

Registration number 337231

Advanced Pharma International Ltd
Directors Report and Financial Statements
For the year ended 31st December 2025

Advanced Pharma International Ltd.

Company Information

Directors	John Doherty Petrina Doherty
Secretary	John Doherty
Company Number	337231
Registered Office	61 Beaubec Dublin Road Drogheda Co. Louth
Business Address	61 Beaubec Dublin Road Drogheda Co. Louth
Bankers	Bank of Ireland Drogheda Co. Louth

Advanced Pharma International Ltd.

Contents

	Page
Directors' Report	1
Balance Sheet	2
Statement of Directors' responsibilities	3
Notes to Financial Statements	4-6

Advanced Pharma International Ltd.

**Directors' Report
For the year ended 31st December 2025**

The Directors present their report and the financial statements for the year ended 31st December 2025.

Principal activity and business review

The principal activity of the company is in the provision of consultancy services to the pharmaceutical sector.

Results and Dividends

The results for the year are set out on page 3.

The Directors do not recommend payment of a final dividend.

Directors and their interests in the Shares of the company

The Directors who served during the year and their interests in the company are as stated below:

	Ordinary Shares	
	31/12/2025	01/01/2025
John Doherty	2	2
Petrina Doherty	2	2

There were no changes in shareholdings between 31st December 2025 and the date of signing the financial statements.

Accounting Records

The Directors acknowledge their responsibility under section 202 of the Companies Act 1990 to keep proper books and records of the Company.

To this end we employ a Director as a bookkeeper. Our books and records are kept at our registered office.

This report was approved by the Board on 8th Jan 2026 and signed on its behalf by



John Doherty
Director




Petrina Doherty
Director


Advanced Pharma International Ltd.

**Balance Sheet
as at 31st December 2025**

	Notes	€	2025	€	€	2024	€
Fixed Assets							
Tangible Assets		0			0		
Current Assets							
Other Debtors		7,265			201		
Cash at bank and in hand		8,550			23,059		
		<u>15,815</u>			<u>23,260</u>		
Creditors: amounts falling due within one year							
PAYE revenue 1,153 and VAT 1,771							
Corporation tax due is 0, (400 was already paid in 2025 for Laya rebate)							
credit card 700, charity 500			4,129			12,458	
Net current assets/liabilities			<u>11,686</u>			<u>10,802</u>	
Net assets			<u>11,686</u>			<u>10,802</u>	
Capital and reserves							
Called up share capital			4			4	
Profit and loss account			(138,132)			(140,226)	
Share holders' funds			<u>(138,128)</u>			<u>(140,222)</u>	

Approved on behalf of the Board
8th Jan 2026


John Doherty
Director


Petrina Doherty
Director

Advanced Pharma International Ltd.

Statement of Directors responsibilities and declaration of unaudited financial statements

The Directors made the following statement in respect of the unaudited financial statements:

General Responsibilities


We as Directors of Advanced Pharma International Ltd state that:

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in s.358 are satisfied,
- (c) the shareholders of the company have not served a notice on the company under s.334(1) in accordance with s.334(2),
- (d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare Financial Statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a year and to otherwise comply with the provisions of Companies Act 2014 relating to Financial Statements so far as they are applicable to the company,
- (e) the company has relied on the specified exemption contained in s.352 Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged Financial Statements have been properly prepared in accordance with s.353 Companies Act 2014.

On behalf of the Board

8th Jan 2026


John Doherty
Director


Petrina Doherty
Director

Advanced Pharma International Ltd.

Notes to the financial statements

For the year ended 31st December 2025

1. Accounting policies

1.1 Accounting convention

The financial statements are prepared under the historical cost convention.

The company has taken advantage of the exemption in FRSI from the requirement to produce a cash flow statement because it is a small company.

1.2 Turnover

Turnover represents the total invoice value, excluding VAT, of sales made during the year.

1.3 Tangible fixed assets and depreciation

Depreciation is provided at rates calculated to write off the cost less residual value of each asset over its expected useful life, as follows:

Computer and office equipment – 25% straight line.

1.4 Pensions

The pension costs charged in the financial statements represent the contribution payable by the company during the year.

2. Turnover

Turnover represents the total invoice value, excluding VAT, of sales made during the year. All turnover in 2025 was generated by clients in Ireland.

3. Operating profit

	2025	2024
	€	€
Operating profit is stated after charging:		
Depreciation and other amounts written off tangible assets	0	0
Accountants	0	0
GCP consultants	0	2,653

4. Directors' Emoluments

There were no employees during the year apart from the Directors.

	2024	2023
	€	€
Remuneration and other emoluments	27,460	102,072
Pension contributions	0	0

Advanced Pharma International Ltd.

Notes to the financial statements

For the year ended 31st December 2025

.....continued

5. Pension costs

The full details of the pension scheme are shown here in this paragraph. A Euro 0 contribution was made to pensions in 2025.

6. Tangible fixed assets

	Computer Equipment	Fixtures and Fittings	Total
	€	€	€
Cost			
As at 1 st Jan 2025	11,274	9,741	21,015
Additions (computer)	0	0	0
As at 31 st December 2025	<u>11,274</u>	<u>9,741</u>	<u>21,015</u>
Depreciation (25% on all)			
Value As at 1 st Jan 2025	0	0	0
Charge for the year	0	0	0
As at 31 st December 2025	<u>11,274</u>	<u>9,741</u>	<u>21,015</u>
Net book values			
As at 31 st December 2025	<u>0</u>	<u>0</u>	<u>0</u>

Advanced Pharma International Ltd.
Notes to the financial statements
For the year ended 31st December 2025

.....continued

7. Share Capital

	2025	2024
	€	€
Authorised equity		
1,000,000 ordinary shares of €1 each	1,000,000	1,000,000
	<u> </u>	<u> </u>
Allotted, called up and fully paid equity		
4 ordinary shares of €1 each	4	4
	<u> </u>	<u> </u>


8. Transactions with Directors

The Directors had no interest free loans during the year, and at year end there was no balance of Euro expenses due from 2025 to be repaid. The movements on these loans are as follows (brackets indicate balance is due to Director):


	Amount Owing		Maximum in any year
	2025	2024	
	€	€	
John Doherty	0	201	(52,338)

Approval of financial statements

The financial statements were approved by the board on 8th Jan 2026 and signed on its behalf



John Doherty
Director



Petrina Doherty
Director